{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:51:12Z","timestamp":1773838272595,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jneuroim.2017.10.006","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T00:16:22Z","timestamp":1507940182000},"page":"118-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy"],"prefix":"10.1016","volume":"313","author":[{"given":"William A.","family":"Stokes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman J.","family":"Oweida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur K.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad G.","family":"Rusthoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana D.","family":"Karam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2017.10.006_bb0005","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0010","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO;2-E","article-title":"Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival","volume":"42","author":"Amer","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0020","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0025","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0035","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/COC.0b013e3181f9456a","article-title":"Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma","volume":"34","author":"Bedikian","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0040","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s12032-013-0466-2","article-title":"Predictors and survival in patients with melanoma brain metastases","volume":"30","author":"Bottoni","year":"2013","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0045","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0050","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2017.01.007","article-title":"Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies","volume":"75","author":"Choong","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0055","series-title":"SAS Global Forum","first-page":"1","article-title":"Local and global optimal propensity score matching","author":"Coca-Perraillon","year":"2007"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.6004\/jnccn.2016.0051","article-title":"Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Coit","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0065","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0070","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0075","doi-asserted-by":"crossref","first-page":"e28499","DOI":"10.4161\/onci.28499","article-title":"Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression","volume":"3","author":"Deng","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0080","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(12)70324-8","article-title":"Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial","volume":"13","author":"Di Giacomo","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1748-717X-9-143","article-title":"The role of whole brain radiation therapy in the management of melanoma brain metastases","volume":"9","author":"Dyer","year":"2014","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-014-1617-9","article-title":"Ipilimumab and whole brain radiation therapy for melanoma brain metastases","volume":"121","author":"Gerber","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0095","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0105","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0360-3016(99)00198-4","article-title":"Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases","volume":"45","author":"Kondziolka","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0135","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0140","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e32835f3d90","article-title":"Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery","volume":"23","author":"Mathew","year":"2013","journal-title":"Melanoma Res."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0150","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.wneu.2013.02.025","article-title":"Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases","volume":"82","author":"Neal","year":"2014","journal-title":"World Neurosurg."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0155","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/bjc.2017.142","article-title":"Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases","volume":"116","author":"Parakh","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0160","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0165","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.280.17.1485","article-title":"Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial","volume":"280","author":"Patchell","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0170","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0175","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0180","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma","volume":"88","author":"Sampson","year":"1998","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0190","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0195","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0200","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cam4.140","article-title":"Ipilimumab and radiation therapy for melanoma brain metastases","volume":"2","author":"Silk","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0210","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204","volume":"35","author":"Tawbi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0215","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0220","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0225","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2017.10.006_bb0230","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557281730423X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557281730423X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:32:11Z","timestamp":1759048331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557281730423X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":46,"alternative-id":["S016557281730423X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.10.006","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}